Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus
Nvidia's earnings and Anthropic's IPO are key market catalysts. Nvidia, led by interim CEO Kress, reports Q3 results on Nov. 17. Analysts expect robust demand metrics. Meanwhile, Anthropic's IPO could value the AI firm at $1.4T. Oil prices fell on Trump's Iran remarks. Summit Therapeutics (SMMT) dropped 20% after FDA rejection, Nebius (NBIS) fell 4% on weak results, Helus Pharma (HELP) rose 23% ahead of Phase 3 data, and MicroStrategy (MSTR) dropped 7% with Bitcoin.
How this was made

The 30-second read
Why it matters
Most of the listed moves are reactions to fresh corporate events (FDA decision, earnings miss, upcoming trial data, crypto price swing).
Market read
The article provides fresh, actionable information on four U.S.-listed stocks, each reacting to a distinct catalyst.
What to watch
Helus Pharma’s upcoming data could trigger a larger sector rally in mental‑health therapeutics.
Background
The article is a futures and market‑wrap piece highlighting upcoming earnings, an IPO, Fed minutes, and several individual stock moves.
Ticker impact
Summit Therapeutics shares fell ~20% after FDA rejected its ivonescimab application.
downward pressure as investors reassess pipeline prospects
FDA rejection is a material negative event for a biotech; market already reacted sharply.
Nebius Group stock slipped ~4% following weak quarterly results and analyst target cuts.
continued pressure unless new guidance improves
Earnings miss and target cuts are fresh negative catalysts.
Helus Pharma surged >23% ahead of its Phase 3 APPROACH study readout scheduled for Monday.
potential upside if Phase 3 data are positive, risk of pull‑back if not
Market is pricing in a favorable outcome; actual data will confirm.
MicroStrategy fell >7% as Bitcoin prices entered a deep rout.
downward pressure tracking Bitcoin’s trajectory
MSTR’s valuation is heavily linked to BTC; a sustained crypto sell‑off hurts the stock.
Market effects
Biotech sector faces regulatory risk; crypto‑linked stocks remain volatile.
U.S. equities see pressure from biotech setbacks and crypto weakness.
Limited to U.S. listed companies; no broad macro shift.
Counterpoint
Biotech investors may view FDA rejection as a catalyst for a turnaround if the company pivots.
Key entities
- companySummit Therapeutics
Biopharma with FDA‑rejected drug.
- companyNebius Group
Cloud‑software firm reporting weak results.
- companyHelus Pharma
Psychiatric drug developer awaiting Phase 3 readout.
- companyMicroStrategy
Bitcoin‑focused firm impacted by crypto price decline.



